Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net)
Introduction Long‐acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We describe a service evaluation of delivery processes and outcomes in 12 clinics. Methods Centres popul...
Gespeichert in:
| Veröffentlicht in: | HIV medicine 2024-10, Vol.25 (10), p.1125-1134 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1134 |
|---|---|
| container_issue | 10 |
| container_start_page | 1125 |
| container_title | HIV medicine |
| container_volume | 25 |
| creator | Ring, Kyle Smuk, Melanie Shongwe, Moses Okonta, Leroy Mackie, Nicola E. Ayres, Sara Barber, Tristan J. Akodu, Jane Ferro, Filippo Chilton, Daniella Hurn, Eliot Halai, Bhavna Barchi, Will Ali, Asim Darko, Sandra White, Gemma Clarke, Emily Clark, Fiona Ali, Bazga Arumainayagam, Joseph Quinn, Gaynor Boffito, Marta Byrne, Ruth Naous, Nadia Leung, Suki Umaipalan, Athavan Thornton, Brian Bayliss, David McLoughlin, Catherine Foster, Jonathan Waters, Laura Orkin, Chloe |
| description | Introduction
Long‐acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We describe a service evaluation of delivery processes and outcomes in 12 clinics.
Methods
Centres populated a database using information from local policies and clinical records. Services were asked to describe approval processes, clinic pathways, and adherence to national guidelines. Additional data were collected on reasons for regimen choice, treatment discontinuations, and management of viraemia.
Results
In total, 518 adults from 12 clinics were approved for CAB + RPV LAI between February 2022 and December 2023. Of the 518 people approved for CAB + RPV LAI, 423 received at least one injection. Median duration on CAB + RPV was 7.5 months (interquartile range 3.7–11.3). In total, 97% of injections were administered within the ±7‐day window. Virological failure occurred in 0.7%, and 6% discontinued CAB + RPV.
Conclusion
In this large UK‐based cohort, robust approval processes and clinic protocols facilitated on‐time injections and low rates of both discontinuation and virological failure. |
| doi_str_mv | 10.1111/hiv.13679 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3066793273</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3113452847</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2789-b547615a2c5d09d9bd8a496ac58e5b42e3338ad64c8f8a1197c5696e00421a0e3</originalsourceid><addsrcrecordid>eNp1kc9uEzEQxi0EoqVw4AWQJS7tYVv_2fXax6gqJCKoElCultc7AUeOHezdrXLjxJln7JPUJIVDJeYyM5qfPs3Mh9BrSs5piYvvbjqnXLTqCTqmtZAVZYo_3dd1xYRgR-hFzmtCaMsVeY6OuJSNZIwdo18fRz84C2FIgDOkqdQYJuNHM7gYcFxhF9ZgB9N5wNZ0cYBvyUwuYRN6nJzfutK4ALgH7yZIu_0gjoONG8jY2BRzxpThmw_Yeheczfj083z26QovZ4u7n78DDGcv0bOV8RlePeQTdPPu6svlvFpev19czpaVZa1UVdfUraCNYbbpiepV10tTK2FsI6Hpagacc2l6UVu5koZS1dpGKAGE1IwaAvwEnR50tyn-GCEPeuOyBe9NgDhmzYkob-Ss5QV9-whdxzGFsp3mlPK6YbJuC3V2oPZnJljpbXIbk3aaEv3HHF3M0XtzCvvmQXHsNtD_I_-6UYCLA3DrPOz-r6Tni68HyXs9wpl_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3113452847</pqid></control><display><type>article</type><title>Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net)</title><source>Wiley Online Library All Journals</source><creator>Ring, Kyle ; Smuk, Melanie ; Shongwe, Moses ; Okonta, Leroy ; Mackie, Nicola E. ; Ayres, Sara ; Barber, Tristan J. ; Akodu, Jane ; Ferro, Filippo ; Chilton, Daniella ; Hurn, Eliot ; Halai, Bhavna ; Barchi, Will ; Ali, Asim ; Darko, Sandra ; White, Gemma ; Clarke, Emily ; Clark, Fiona ; Ali, Bazga ; Arumainayagam, Joseph ; Quinn, Gaynor ; Boffito, Marta ; Byrne, Ruth ; Naous, Nadia ; Leung, Suki ; Umaipalan, Athavan ; Thornton, Brian ; Bayliss, David ; McLoughlin, Catherine ; Foster, Jonathan ; Waters, Laura ; Orkin, Chloe</creator><creatorcontrib>Ring, Kyle ; Smuk, Melanie ; Shongwe, Moses ; Okonta, Leroy ; Mackie, Nicola E. ; Ayres, Sara ; Barber, Tristan J. ; Akodu, Jane ; Ferro, Filippo ; Chilton, Daniella ; Hurn, Eliot ; Halai, Bhavna ; Barchi, Will ; Ali, Asim ; Darko, Sandra ; White, Gemma ; Clarke, Emily ; Clark, Fiona ; Ali, Bazga ; Arumainayagam, Joseph ; Quinn, Gaynor ; Boffito, Marta ; Byrne, Ruth ; Naous, Nadia ; Leung, Suki ; Umaipalan, Athavan ; Thornton, Brian ; Bayliss, David ; McLoughlin, Catherine ; Foster, Jonathan ; Waters, Laura ; Orkin, Chloe</creatorcontrib><description>Introduction
Long‐acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We describe a service evaluation of delivery processes and outcomes in 12 clinics.
Methods
Centres populated a database using information from local policies and clinical records. Services were asked to describe approval processes, clinic pathways, and adherence to national guidelines. Additional data were collected on reasons for regimen choice, treatment discontinuations, and management of viraemia.
Results
In total, 518 adults from 12 clinics were approved for CAB + RPV LAI between February 2022 and December 2023. Of the 518 people approved for CAB + RPV LAI, 423 received at least one injection. Median duration on CAB + RPV was 7.5 months (interquartile range 3.7–11.3). In total, 97% of injections were administered within the ±7‐day window. Virological failure occurred in 0.7%, and 6% discontinued CAB + RPV.
Conclusion
In this large UK‐based cohort, robust approval processes and clinic protocols facilitated on‐time injections and low rates of both discontinuation and virological failure.</description><identifier>ISSN: 1464-2662</identifier><identifier>ISSN: 1468-1293</identifier><identifier>EISSN: 1468-1293</identifier><identifier>DOI: 10.1111/hiv.13679</identifier><identifier>PMID: 38858222</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Adults ; Cabotegravir ; capacity ; Clinics ; discontinuation ; effectiveness ; HIV ; Information processing ; long‐acting injectable ; real‐world evidence ; Rilpivirine ; Viremia ; Virologic suppression</subject><ispartof>HIV medicine, 2024-10, Vol.25 (10), p.1125-1134</ispartof><rights>2024 The Author(s). published by John Wiley & Sons Ltd on behalf of British HIV Association.</rights><rights>2024 The Author(s). HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2789-b547615a2c5d09d9bd8a496ac58e5b42e3338ad64c8f8a1197c5696e00421a0e3</cites><orcidid>0000-0002-1379-1775 ; 0000-0003-4016-4643 ; 0000-0003-1254-9853 ; 0000-0001-6168-6745 ; 0000-0001-7340-5517 ; 0000-0002-7527-479X ; 0000-0003-1914-4891</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhiv.13679$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhiv.13679$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38858222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ring, Kyle</creatorcontrib><creatorcontrib>Smuk, Melanie</creatorcontrib><creatorcontrib>Shongwe, Moses</creatorcontrib><creatorcontrib>Okonta, Leroy</creatorcontrib><creatorcontrib>Mackie, Nicola E.</creatorcontrib><creatorcontrib>Ayres, Sara</creatorcontrib><creatorcontrib>Barber, Tristan J.</creatorcontrib><creatorcontrib>Akodu, Jane</creatorcontrib><creatorcontrib>Ferro, Filippo</creatorcontrib><creatorcontrib>Chilton, Daniella</creatorcontrib><creatorcontrib>Hurn, Eliot</creatorcontrib><creatorcontrib>Halai, Bhavna</creatorcontrib><creatorcontrib>Barchi, Will</creatorcontrib><creatorcontrib>Ali, Asim</creatorcontrib><creatorcontrib>Darko, Sandra</creatorcontrib><creatorcontrib>White, Gemma</creatorcontrib><creatorcontrib>Clarke, Emily</creatorcontrib><creatorcontrib>Clark, Fiona</creatorcontrib><creatorcontrib>Ali, Bazga</creatorcontrib><creatorcontrib>Arumainayagam, Joseph</creatorcontrib><creatorcontrib>Quinn, Gaynor</creatorcontrib><creatorcontrib>Boffito, Marta</creatorcontrib><creatorcontrib>Byrne, Ruth</creatorcontrib><creatorcontrib>Naous, Nadia</creatorcontrib><creatorcontrib>Leung, Suki</creatorcontrib><creatorcontrib>Umaipalan, Athavan</creatorcontrib><creatorcontrib>Thornton, Brian</creatorcontrib><creatorcontrib>Bayliss, David</creatorcontrib><creatorcontrib>McLoughlin, Catherine</creatorcontrib><creatorcontrib>Foster, Jonathan</creatorcontrib><creatorcontrib>Waters, Laura</creatorcontrib><creatorcontrib>Orkin, Chloe</creatorcontrib><title>Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net)</title><title>HIV medicine</title><addtitle>HIV Med</addtitle><description>Introduction
Long‐acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We describe a service evaluation of delivery processes and outcomes in 12 clinics.
Methods
Centres populated a database using information from local policies and clinical records. Services were asked to describe approval processes, clinic pathways, and adherence to national guidelines. Additional data were collected on reasons for regimen choice, treatment discontinuations, and management of viraemia.
Results
In total, 518 adults from 12 clinics were approved for CAB + RPV LAI between February 2022 and December 2023. Of the 518 people approved for CAB + RPV LAI, 423 received at least one injection. Median duration on CAB + RPV was 7.5 months (interquartile range 3.7–11.3). In total, 97% of injections were administered within the ±7‐day window. Virological failure occurred in 0.7%, and 6% discontinued CAB + RPV.
Conclusion
In this large UK‐based cohort, robust approval processes and clinic protocols facilitated on‐time injections and low rates of both discontinuation and virological failure.</description><subject>Adults</subject><subject>Cabotegravir</subject><subject>capacity</subject><subject>Clinics</subject><subject>discontinuation</subject><subject>effectiveness</subject><subject>HIV</subject><subject>Information processing</subject><subject>long‐acting injectable</subject><subject>real‐world evidence</subject><subject>Rilpivirine</subject><subject>Viremia</subject><subject>Virologic suppression</subject><issn>1464-2662</issn><issn>1468-1293</issn><issn>1468-1293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kc9uEzEQxi0EoqVw4AWQJS7tYVv_2fXax6gqJCKoElCultc7AUeOHezdrXLjxJln7JPUJIVDJeYyM5qfPs3Mh9BrSs5piYvvbjqnXLTqCTqmtZAVZYo_3dd1xYRgR-hFzmtCaMsVeY6OuJSNZIwdo18fRz84C2FIgDOkqdQYJuNHM7gYcFxhF9ZgB9N5wNZ0cYBvyUwuYRN6nJzfutK4ALgH7yZIu_0gjoONG8jY2BRzxpThmw_Yeheczfj083z26QovZ4u7n78DDGcv0bOV8RlePeQTdPPu6svlvFpev19czpaVZa1UVdfUraCNYbbpiepV10tTK2FsI6Hpagacc2l6UVu5koZS1dpGKAGE1IwaAvwEnR50tyn-GCEPeuOyBe9NgDhmzYkob-Ss5QV9-whdxzGFsp3mlPK6YbJuC3V2oPZnJljpbXIbk3aaEv3HHF3M0XtzCvvmQXHsNtD_I_-6UYCLA3DrPOz-r6Tni68HyXs9wpl_</recordid><startdate>202410</startdate><enddate>202410</enddate><creator>Ring, Kyle</creator><creator>Smuk, Melanie</creator><creator>Shongwe, Moses</creator><creator>Okonta, Leroy</creator><creator>Mackie, Nicola E.</creator><creator>Ayres, Sara</creator><creator>Barber, Tristan J.</creator><creator>Akodu, Jane</creator><creator>Ferro, Filippo</creator><creator>Chilton, Daniella</creator><creator>Hurn, Eliot</creator><creator>Halai, Bhavna</creator><creator>Barchi, Will</creator><creator>Ali, Asim</creator><creator>Darko, Sandra</creator><creator>White, Gemma</creator><creator>Clarke, Emily</creator><creator>Clark, Fiona</creator><creator>Ali, Bazga</creator><creator>Arumainayagam, Joseph</creator><creator>Quinn, Gaynor</creator><creator>Boffito, Marta</creator><creator>Byrne, Ruth</creator><creator>Naous, Nadia</creator><creator>Leung, Suki</creator><creator>Umaipalan, Athavan</creator><creator>Thornton, Brian</creator><creator>Bayliss, David</creator><creator>McLoughlin, Catherine</creator><creator>Foster, Jonathan</creator><creator>Waters, Laura</creator><creator>Orkin, Chloe</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1379-1775</orcidid><orcidid>https://orcid.org/0000-0003-4016-4643</orcidid><orcidid>https://orcid.org/0000-0003-1254-9853</orcidid><orcidid>https://orcid.org/0000-0001-6168-6745</orcidid><orcidid>https://orcid.org/0000-0001-7340-5517</orcidid><orcidid>https://orcid.org/0000-0002-7527-479X</orcidid><orcidid>https://orcid.org/0000-0003-1914-4891</orcidid></search><sort><creationdate>202410</creationdate><title>Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net)</title><author>Ring, Kyle ; Smuk, Melanie ; Shongwe, Moses ; Okonta, Leroy ; Mackie, Nicola E. ; Ayres, Sara ; Barber, Tristan J. ; Akodu, Jane ; Ferro, Filippo ; Chilton, Daniella ; Hurn, Eliot ; Halai, Bhavna ; Barchi, Will ; Ali, Asim ; Darko, Sandra ; White, Gemma ; Clarke, Emily ; Clark, Fiona ; Ali, Bazga ; Arumainayagam, Joseph ; Quinn, Gaynor ; Boffito, Marta ; Byrne, Ruth ; Naous, Nadia ; Leung, Suki ; Umaipalan, Athavan ; Thornton, Brian ; Bayliss, David ; McLoughlin, Catherine ; Foster, Jonathan ; Waters, Laura ; Orkin, Chloe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2789-b547615a2c5d09d9bd8a496ac58e5b42e3338ad64c8f8a1197c5696e00421a0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adults</topic><topic>Cabotegravir</topic><topic>capacity</topic><topic>Clinics</topic><topic>discontinuation</topic><topic>effectiveness</topic><topic>HIV</topic><topic>Information processing</topic><topic>long‐acting injectable</topic><topic>real‐world evidence</topic><topic>Rilpivirine</topic><topic>Viremia</topic><topic>Virologic suppression</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ring, Kyle</creatorcontrib><creatorcontrib>Smuk, Melanie</creatorcontrib><creatorcontrib>Shongwe, Moses</creatorcontrib><creatorcontrib>Okonta, Leroy</creatorcontrib><creatorcontrib>Mackie, Nicola E.</creatorcontrib><creatorcontrib>Ayres, Sara</creatorcontrib><creatorcontrib>Barber, Tristan J.</creatorcontrib><creatorcontrib>Akodu, Jane</creatorcontrib><creatorcontrib>Ferro, Filippo</creatorcontrib><creatorcontrib>Chilton, Daniella</creatorcontrib><creatorcontrib>Hurn, Eliot</creatorcontrib><creatorcontrib>Halai, Bhavna</creatorcontrib><creatorcontrib>Barchi, Will</creatorcontrib><creatorcontrib>Ali, Asim</creatorcontrib><creatorcontrib>Darko, Sandra</creatorcontrib><creatorcontrib>White, Gemma</creatorcontrib><creatorcontrib>Clarke, Emily</creatorcontrib><creatorcontrib>Clark, Fiona</creatorcontrib><creatorcontrib>Ali, Bazga</creatorcontrib><creatorcontrib>Arumainayagam, Joseph</creatorcontrib><creatorcontrib>Quinn, Gaynor</creatorcontrib><creatorcontrib>Boffito, Marta</creatorcontrib><creatorcontrib>Byrne, Ruth</creatorcontrib><creatorcontrib>Naous, Nadia</creatorcontrib><creatorcontrib>Leung, Suki</creatorcontrib><creatorcontrib>Umaipalan, Athavan</creatorcontrib><creatorcontrib>Thornton, Brian</creatorcontrib><creatorcontrib>Bayliss, David</creatorcontrib><creatorcontrib>McLoughlin, Catherine</creatorcontrib><creatorcontrib>Foster, Jonathan</creatorcontrib><creatorcontrib>Waters, Laura</creatorcontrib><creatorcontrib>Orkin, Chloe</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>HIV medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ring, Kyle</au><au>Smuk, Melanie</au><au>Shongwe, Moses</au><au>Okonta, Leroy</au><au>Mackie, Nicola E.</au><au>Ayres, Sara</au><au>Barber, Tristan J.</au><au>Akodu, Jane</au><au>Ferro, Filippo</au><au>Chilton, Daniella</au><au>Hurn, Eliot</au><au>Halai, Bhavna</au><au>Barchi, Will</au><au>Ali, Asim</au><au>Darko, Sandra</au><au>White, Gemma</au><au>Clarke, Emily</au><au>Clark, Fiona</au><au>Ali, Bazga</au><au>Arumainayagam, Joseph</au><au>Quinn, Gaynor</au><au>Boffito, Marta</au><au>Byrne, Ruth</au><au>Naous, Nadia</au><au>Leung, Suki</au><au>Umaipalan, Athavan</au><au>Thornton, Brian</au><au>Bayliss, David</au><au>McLoughlin, Catherine</au><au>Foster, Jonathan</au><au>Waters, Laura</au><au>Orkin, Chloe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net)</atitle><jtitle>HIV medicine</jtitle><addtitle>HIV Med</addtitle><date>2024-10</date><risdate>2024</risdate><volume>25</volume><issue>10</issue><spage>1125</spage><epage>1134</epage><pages>1125-1134</pages><issn>1464-2662</issn><issn>1468-1293</issn><eissn>1468-1293</eissn><abstract>Introduction
Long‐acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We describe a service evaluation of delivery processes and outcomes in 12 clinics.
Methods
Centres populated a database using information from local policies and clinical records. Services were asked to describe approval processes, clinic pathways, and adherence to national guidelines. Additional data were collected on reasons for regimen choice, treatment discontinuations, and management of viraemia.
Results
In total, 518 adults from 12 clinics were approved for CAB + RPV LAI between February 2022 and December 2023. Of the 518 people approved for CAB + RPV LAI, 423 received at least one injection. Median duration on CAB + RPV was 7.5 months (interquartile range 3.7–11.3). In total, 97% of injections were administered within the ±7‐day window. Virological failure occurred in 0.7%, and 6% discontinued CAB + RPV.
Conclusion
In this large UK‐based cohort, robust approval processes and clinic protocols facilitated on‐time injections and low rates of both discontinuation and virological failure.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38858222</pmid><doi>10.1111/hiv.13679</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-1379-1775</orcidid><orcidid>https://orcid.org/0000-0003-4016-4643</orcidid><orcidid>https://orcid.org/0000-0003-1254-9853</orcidid><orcidid>https://orcid.org/0000-0001-6168-6745</orcidid><orcidid>https://orcid.org/0000-0001-7340-5517</orcidid><orcidid>https://orcid.org/0000-0002-7527-479X</orcidid><orcidid>https://orcid.org/0000-0003-1914-4891</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1464-2662 |
| ispartof | HIV medicine, 2024-10, Vol.25 (10), p.1125-1134 |
| issn | 1464-2662 1468-1293 1468-1293 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3066793273 |
| source | Wiley Online Library All Journals |
| subjects | Adults Cabotegravir capacity Clinics discontinuation effectiveness HIV Information processing long‐acting injectable real‐world evidence Rilpivirine Viremia Virologic suppression |
| title | Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI‐net) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T16%3A19%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multicentre%20service%20evaluation%20of%20injectable%20cabotegravir%20and%20rilpivirine%20delivery%20and%20outcomes%20across%2012%20UK%20clinics%20(SHARE%20LAI%E2%80%90net)&rft.jtitle=HIV%20medicine&rft.au=Ring,%20Kyle&rft.date=2024-10&rft.volume=25&rft.issue=10&rft.spage=1125&rft.epage=1134&rft.pages=1125-1134&rft.issn=1464-2662&rft.eissn=1468-1293&rft_id=info:doi/10.1111/hiv.13679&rft_dat=%3Cproquest_cross%3E3113452847%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3113452847&rft_id=info:pmid/38858222&rfr_iscdi=true |